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ABSTRACT As a model for the detection ofhuman genetic
disease in preimplantation embryos, we describe a method in
which trophectoderm biopsy samples from viable mouse blas-
tocysts are simultaneously analyzed for the presence of a
normal or mutant allele of the myelin basic protein gene by the
polymerase chain reaction. The biopsied embryos are kept in
culture during analysis of biopsied material and later reintro-
duced to a foster mother. Prenatal diagnosis can be completed
in less than 7 hr. The identity of either amplification product
was proved conclusively by direct sequence analysis of ampli-
fied products. Ninety-six percent of recovered blastocysts sur-
vived biopsy, as judged by re-formation of a blastocyst cavity
in culture. Fifty-nine percent of the biopsied embryos estab-
lished pregnancy by day 6.5, compared to 88% of unmanipu-
lated controls. This approach can be applied to preimplanta-
tion diagnosis of human genetic diseases by using extraembry-
onic cells from blastocysts obtained after in vitro fertilization or
uterine lavage. It will make possible the elimination of a mutant
allele from a family in a single generation.
The prevention of genetic diseases is a major goal of modern
medicine. To date, prevention has been achieved by genetic
counseling for identified carriers wishing to have children and
by antenatal diagnosis of a small number of diseases by
biochemical assay (Tay-Sachs disease) or karyotyping
(Down syndrome) of material obtained by amniocentesis or
chorionic villus biopsy followed by elective pregnancy ter-
mination. As DNA sequence characterization of genetic
defects continues, the ability to diagnose a wide variety of
genetic diseases by direct analysis of DNA is becoming
possible. As techniques for embryo manipulation (1) and
diagnostic molecular biology (2, 3) improve, the prospect of
prevention of genetic disease by preimplantation diagnosis
provides an alternative to intrauterine diagnosis and the
termination of pregnancy. In vitro fertilization has become a
routine procedure in fertility clinics. Gene detection in pre-
implantation embryos obtained either by lavage or by in vitro
fertilization would permit the introduction and implantation
of embryos lacking the mutant allele and the eventual birth of
normal children, thus preventing the transmission of mutant
alleles from parents to their offspring. We present here a
strategy that would permit human preimplantation embryos
to be sampled harmlessly by biopsy, screened for genetic
defects, and introduced into the mother.
We used as a model the mouse mutation shiverer (shi/shi).
The shiverer mutant is characterized by tremors, hypomy-
elination of the central nervous system, and a shortened
life-span (reviewed in ref. 4). The gene encoding myelin basic
protein (MBP), a major constituent of the central nervous
system myelin, has been largely deleted in shiverer mice (5).
The normal MBP gene has seven exons (6, 7), which have
been sequenced (6), while the mutant MBP gene has only
exons I and II (5, 8). The 5' breakpoint of the MBP gene
deletion in shiverer mice has been sequenced (8). Our aim
was to identify the mutant and normal MBP genes in biopsied
extraembryonic material in sufficient time to allow transfer of
assayed, preselected embryos to pseudopregnant recipients.
MATERIALS AND METHODS
Blastocysts were flushed from the uterine horns on the fourth
day of pregnancy and incubated in M16 medium (9) at 370C
and 5% CO2. For the biopsy, blastocysts were placed in a
drop ofM2 medium (10) with bovine serum albumin replaced
by polyvinylpyrrolidone (1 mg/ml) and were covered with
light paraffin oil. One to three or three to five extraembryonic
trophectoderm cells were removed using glass needles at-
tached to micromanipulators as described previously (11).
After this operation, blastocysts were returned to M16 me-
dium and the biopsied cells were placed in tubes in 10 Al of
distilled water, frozen on dry ice, and stored at -70°C prior
to analysis. The blastocysts were scored 7-12 hr later for
recovery as judged by the reappearance of the blastocele
cavity. Five to eight viable blastocysts were transferred to
the uterine horns of pseudopregnant recipient females on day
3 of pregnancy. Each recipient had control embryos trans-
ferred to one horn and biopsied embryos transferred to the
contralateral horn. The recipients were sacrificed at day 7 or
days 12-15 of pregnancy to score for implantation sites or
viable fetuses. In a few cases pregnancy was allowed to go to
term.
The presence of wild-type or mutant MBP alleles in the
biopsy sample was detected using two sets of specific primers
in the polymerase chain reaction (PCR). One set of synthetic
oligonucleotide primers amplifies a 169-base-pair (bp) frag-
ment from wild-type mouse DNA; these primers have se-
quences complementary to intron sequences flanking exon
VI of the MBP gene (exon V in ref. 6) (5'-AGCTCTGGTCTT-
TCTTGCAG-3'and 5'-CCCCGTGGTAGGAATATTACAT-
AAC-3'). As exons II-VII are deleted in the shiverer mouse,
these primers do not amplify a fragment when shiverer DNA
is used as a template. The second set of primers amplifies a
380-bp fragment unique to shiverer DNA. These oligonucle-
otide primers are complementary to sequences on either side
of the shiverer "breakpoint," which is within the second
intron of the MBP gene (8). They have sequences comple-
Abbreviations: MBP, myelin basic protein; PCR, polymerase chain
reaction.
tTo whom reprint requests should be addressed.
4481
The publication costs of this article were defrayed in part by page charge
payment. This article must therefore be hereby marked "advertisement"
in accordance with 18 U.S.C. §1734 solely to indicate this fact.
4482 Medical Sciences: Gomez et al.
0.49 _ Shi
0.36 _ _ allele
0.24 ._ +
allele
C Shi/+ Shi/+ - Shi/+ C +1+ +/+ Shl±4 Sh!/Sh Shi Shi
1 2 3 4 5 6 7 8 9 10 11
FIG. 1. Agarose gel analysis of PCR amplification ofDNA in trophectoderm biopsy samples. Lanes 10 and 11, amplifications ofDNA from
trophectoderm biopsy material of homozygous shiverer (shi/shi) blastocysts. Lanes 2, 3, and 9, amplifications of DNA from heterozygous
(shi/+) blastocysts (lane 3 false negative). Lanes 7 and 8, amplifications of DNA from homozygous wild-type (+/+) blastocysts. Lane 5,
amplification of DNA from whole heterozygous (shi/+) blastocyst. Lanes 1 and 6, amplifications of medium control. Lane 4, empty lane.
mentary to nucleotides 201-225 (5'-CAGGGGATGGGGAG-
TCAGAAGTGAG-3') and on the opposite strand from po-
sitions 551-581 (5'-ATGTATGTGTGTGTGTGCTTATC-
TAGTGTA-3') (7). Both sets of primers were used in all the
PCR assays.
The biopsied cells were digested by a modification of the
procedure of Li et al. (2). Briefly, 10 ,ul of digestion mixture
was added to each tube containing cells and distilled water,
to make a final concentration of lx PCR buffer (50 mM
KCl/10 mM Tris-HCl, pH 8.3/2.5 mM MgCl2/0.01% gelatin),
50 ,ug of proteinase K per ml, 20 mM dithiothreitol, and 1.7
,uM SDS. Cells in the digestion mix were incubated at 55°C
for 1 hr, then boiled for 15 min to inactivate proteinase K and
denature DNA. After cooling on ice, 80 ,ul of amplification
master mix was added to each tube to give a final composition
of lx PCR buffer; 0.5 p.M for each of four primers; 2 mM for
dATP, dCTP, dGTP, and dTlP; and 2.5 units of Thermus
aquaticus (Taq) DNA polymerase (Cetus).
High-efficiency amplification in a thermocycler (Perkin-
Elmer) was achieved using 50 cycles (92°C for 30 sec, 60°C for
45 sec, and 72°C for 90 sec) followed by 10 min of extension
at 72°C. An additional aliquot of 2.5 units of Taq polymerase





















FIG. 2. DNA sequence analyses of PCR products from biopsied
embryos. (a) Portion of exon VI (oriented with 5' end downward)
extending from position E98 (6) to 16 bases into the intron following
exon VI (listed as exon V in ref. 6), sequenced from the plus strand.
(b) Portion of shiverer MBP allele containing the breakpoint (arrow-
head) (5' end oriented downward) from nucleotide 420 to nucleotide
462 (from ref. 7), sequenced from the plus strand.
added after the 30th cycle greatly improved the signal. To
avoid contamination with exogenous DNA, strict conditions,
as outlined in ref. 12, were observed at all times. For analysis,
10 ,1l of each amplification mixture was electrophoresed in a
1.5% agarose minigel and screened for the presence of bands
of expected size.
Direct sequence analysis of PCR products was performed
according to Kretz et al. (13). Amplified DNA for use as
template was obtained by electrophoresis in 1% low-melting
agarose gel in Tris/borate/EDTA buffer. Bands cut from the
ethidium-stained gel were heated to %WC for 10 min and 7 ,ul
was used immediately as template for standard dideoxy
chain-termination sequencing with phage T7 DNA polymer-
ase (Sequenase; United States Biochemical) except that after
annealing at 55°C for 30 min, all reactions were performed at
370C.
RESULTS
Detection ofMBP Alleles in Trophectoderm Biopsy Samples.
Amplification by PCR using the shiverer breakpoint primers
leads to a 380-bp DNA product when shi/shi DNA is the
template, but no product is observed when wild-type (+/+)
DNA is the template (Fig. 1). Exon VI primers yield a 169-bp
product when +/+ DNA is used as template and no product
when shi/shi DNA serves as template (Fig. 1). This choice of
primers for PCR allows for the simultaneous amplification of
these regions from both alleles when present, and thus
permits one to distinguish heterozygous (shi/+) from ho-
mozygous (shi/shi) embryos.
Table 1. Simultaneous assay of trophectoderm cells for mutant




Genotype of Number allele for other (no allele
blastocyst assayed detected allele detected)
shi/shi 13 6 3 4
shi/+ 7 4 NR* 3
+/+ 12 10Q 4
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Table 2. Summary of various steps in the procedure including embryo biopsy, culture, and
transfer to foster mothers
No. cavitated No. establishing pregnancy/
No. recovered/ after 7-12 hr no. transferred
Blastocysts no. biopsied in culture Day 6.5 Days 12-15
Biopsied 93/133 89 (96%) 22/37 (59%) 10/42 (24%)
Control NR NR 30/34 (88%) 15/42 (36%)
NR, not relevant.
In most trophectoderm biopsies, one or both alleles were
readily detectable. Fig. 1 shows DNA fragments of the
expected size that have been amplified from biopsy material
by PCR and separated by electrophoresis in an agarose gel.
Direct sequence analysis ofthe DNA fragments isolated from
these bands (18 cases) confirmed the identity of these am-
plification products with the expected regions of the MBP
gene (Fig. 2).
Table 1 summarizes the results of assay of 36 trophecto-
derm biopsy samples. In homozygous shiverer embryos the
shiverer allele was detected 6 out of 10 times. In 3 of these 6
cases the homozygous shiverer DNA was contaminated with
normal cells, leading to a false positive for MBP exon VI. In
4 other shiverer homozygote samples no amplification was
obtained. In 4 of 7 heterozygous samples (shi/+) the normal
and mutant alleles were detected; in 3 cases no amplification
was obtained or the PCR reaction failed. In 15 of 19 wild-type
biopsy samples the correct allele was identified and in 4 cases
no amplification was obtained. Thus, in 25 out of 36 trophec-
toderm biopsy samples the expected MBP allele was de-
tected; in the remaining 11 samples no allele was detected
(i.e., false negative results were obtained). Three false pos-
itives were obtained using trophectoderm biopsy samples and
2 false positives were obtained using medium or water.
The analyses were completed and the genotypes of the
blastocysts were identified in 7 hr from the time of biopsy (1
hr for digestion, 6 hr for amplification and separation of
products by agarose gel electrophoresis).
Biopsy and Transplantation of Blastocysts. The viability of
the biopsied embryos was assessed by monitoring the main-
tenance or re-formation of a blastocele cavity and their
subsequent ability to establish pregnancy (implantation
sites), form fetuses (Table 2), or produce live young (Fig. 3).
The viability after biopsy (as judged by recovery of blasto-
cele) (96%) was improved over a previous study (60%) (11).
The implantation rate of biopsied embryos was 59o com-
pared with 88% for control embryos. As judged by develop-
ment of fetuses, the overall success of transfer of both
biopsied (24%) and control unbiopsied (36%) embryos was
lower than in a previous study (11) (36% and 55%, respec-
tively). This was almost certainly due to the inexperience of
the person performing the transplants.
DISCUSSION
Over the next decade the number of genetic diseases that are
characterized at the DNA level will greatly increase (14). One
important application of such knowledge would be the early
detection of harmful mutations in the fetus or the preimplan-
tation embryo.
We have used the shiverer mutant mouse as a model
system for the preimplantation diagnosis of a genetic disease.
Living embryos were biopsied and the DNA was assayed for
the presence of shiverer mutant (shi/shi) and wild-type MBP
genes by PCR. This study demonstrates the practical appli-
cation of a rapid PCR gene-detection assay for screening
preimplantation embryos and transfer of selected normal
embryos to pseudopregnant foster mothers.
At present there are two methods to sample DNA from
preimplantation embryos: (i) removal of a blastomere at the
two- to eight-cell stage (15, 16) and (ii) removal of cells from
the extraembryonic trophectoderm layer of the blastocyst,
so-called trophectoderm biopsy (11). Both biopsy sources
have been used for preimplantation diagnosis of embryos
either by biochemical assays to measure enzyme activity (11)
or by PCR for the detection of a particular mutation (16). We
used trophectoderm biopsy for several reasons: (i) sufficient
material is obtained from trophectoderm biopsy to repeat the
assay if necessary; (ii) the viability of the embryos following
biopsy is good, and the implantation rate is only somewhat
less than that of unmanipulated embryos; and (iii) the portion
of the blastocyst that is sampled, the trophectoderm, is
destined to become placenta and is thus distinct from the
embryo proper. When the use of such techniques on human
embryos is considered, biopsy of trophectoderm may be
ethically more acceptable than removal ofone offour or eight
cells destined to form part of the embryo proper. We believe
that these factors outweigh the disadvantage of trophecto-
derm biopsy, which is that it is technically more difficult than
using blastomeres and it is subject to an increased likelihood
of sample loss.
FIG. 3. Shiverer mouse (at left) born after trophectoderm biopsy and PCR analysis at blastocyst stage. Embryo was maintained in culture
for 10 hr prior to transfer to foster mother (at right). Mice were photographed with slow shutter speed to reveal shiverer phenotype.
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In this study we screened embryos for the presence of the
wild-type or mutant MBP gene. Two sets of oligonucleotide
primers were used in every PCR reaction. One set amplified
a fragment ofDNA that is present only in the wild-type gene,
while the other pair amplified a DNA fragment unique to the
mutated gene. It is important to identify both the normal and
the mutated allele. The dangers of not doing so are best
illustrated by a recent study in which PCR was used to screen
preimplantation embryos for f8-thalassemia (16). One set of
oligonucleotide primers was used to amplify part of the
wild-type hemoglobin gene. Failure to amplify this fragment
was interpreted as absence of the wild-type gene and, by
inference, the presence of the mutant allele. With this strat-
egy it would not be possible to distinguish biopsy material
with mutant alleles from a PCR assay that failed for technical
reasons or the loss of the sample material. More importantly,
heterozygote embryos carrying the mutation could not be
distinguished from wild-type embryos. Finally, if the sample
was contaminated with normal cells, as readily happens, a
mutant embryo would be falsely diagnosed as normal.
The gene-detection procedure provided genotype informa-
tion within 7 hr of biopsy. We were able to detect the correct
MBP alleles in 25 out of 36 cases, with 3 false positives
(incorrect allele also detected) arising from the contamination
of shi/shi embryos with wild-type cells or amplified material.
There were 11 false negatives (no allele detected). The false
negatives were due to either the loss of biopsy material during
transfer of cells from the operating drop to the assay tube or
the failure of the amplification reaction for technical reasons.
We favor the former explanation because, using the same
conditions and oligonucleotides, we were able to detect both
alleles in a single blastomere (data not shown). The important
point is that in every case where PCR products were obtained,
the presence of a mutant allele was correctly established.
In the case of the three false positives both the wild-type
and mutant alleles were detected in biopsies from homozy-
gous shiverer embryos, due to contamination of the biopsy
material with normal mouse genomic. DNA, even when the
strictest precautions were observed (12). Consequently three
of the homozygous shiverer embryos (shi/shi) were misdi-
agnosed as carrier embryos (shi/+). In practice when dealing
with human genetic disease, embryos with either the ho-
mozygous mutant genotype or the heterozygous carrier ge-
notype would not be transplanted. In no case was a shiverer
allele detected in wild-type embryo biopsy material (0/19).
Thus only embryos unequivocally lacking the mutant allele
would be transplanted by our procedure, ensuring the elim-
ination of a given mutant gene from a family in a single
generation and the birth of only genetically normal offspring.
We tested the specificity of our assay directly by sequenc-
ing amplified DNA products after separation in agarose gels
(Fig. 2). We have seen that in the 18 cases tested the fragment
amplified was identical to the region of DNA (exon VI or
breakpoint) flanked by the primers. This latter observation
also demonstrates the power ofPCR amplification, which has
made possible the sequencing of DNA originally amplified
from as few as one or two cells.
A number of embryos (30 out of a total of 133) were lost
during transfer from the drop of medium in which they were
biopsied to the culture medium. The number of embryos
transferred safely would be improved with practice and by
scheduling the biopsy of fewer embryos at a time. If smaller
sample numbers were processed at a time, the in vitro period
following the biopsy would also be reduced, and the transfer
could be undertaken within 10 hr of biopsy. The percentage
ofembryos that survived biopsy was high (96%). This may be
ascribed to the fact that fewer cells need be removed for the
PCR assay as compared to the enzyme assay. Fifty-nine
percent of the viable biopsied embryos implanted as com-
pared to 88% for the unmanipulated control embryos. These
data were not recorded in the previous study (11). Twenty-
four percent of biopsied blastocysts as compared to 36% of
unbiopsied blastocysts were found to have established preg-
nancy in foster mothers sacrificed at days 12-15. The preg-
nancy rates of both biopsied and control embryos were lower
than those reported previously (36% and 55%, respectively).
Because of the inexperience of the investigator performing
the uterine transfers it is likely that these rates would greatly
improve with further practice. The biopsy and culture of
blastocysts seem to have had less effect (as judged by
differences in pregnancy rates) on pregnancy rate in this
study than in the previous one (11). This may be due to the
smaller biopsy size (PCR assay needs fewer cells) or to the
reduced duration in culture.
This strategy may be applied to the screening of human
embryos obtained by in vitro fertilization or lavage to identify
those appropriate for transfer to the mother. This study
illustrates a number of factors that are important to consider.
(i) The method of biopsy is important for the survival of the
embryo as well as the success of the assay. Trophectoderm
biopsy is the method of choice from both standpoints, as it
provides enough material to repeat the assays if necessary
and the survival of the biopsied embryo is good. (ii) The
strictest conditions must be observed to avoid contamination
ofthe sample. Methods for avoiding contamination have been
outlined (12). (iii) DNA primers should be chosen to detect
mutant and normal alleles directly. Both sets of primers
should be able to function together in the same biopsy
sample. (iv) Sequencing of the amplified products should be
done initially to confirm that the correct fragment has been
amplified. (v) Application of other methods ofgene detection,
such as the oligonucleotide ligation assay (3), will allow
detection of any characterized gene mutation including single
base-pair substitutions. Rapid advances are expected in this
important application of clinical genetics and embryology. As
the number of genetic diseases that are characterized at the
DNA level increases, this embryo screening procedure could
be of great use.
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